These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11933558)

  • 1. [Heart failure and vasopeptidase inhibitors].
    Bareiss P; Ohlmann P; Roul G
    Arch Mal Coeur Vaiss; 2002 Feb; 95 Spec 4(5 Spec 4):51-3. PubMed ID: 11933558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasopeptidase inhibitors in heart failure.
    Dawson A; Struthers AD
    J Renin Angiotensin Aldosterone Syst; 2002 Sep; 3(3):156-9. PubMed ID: 12563565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.
    Rouleau JL; Pfeffer MA; Stewart DJ; Isaac D; Sestier F; Kerut EK; Porter CB; Proulx G; Qian C; Block AJ
    Lancet; 2000 Aug; 356(9230):615-20. PubMed ID: 10968433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study.
    Solomon SD; Skali H; Bourgoun M; Fang J; Ghali JK; Martelet M; Wojciechowski D; Ansmite B; Skards J; Laks T; Henry D; Packer M; Pfeffer MA;
    Am Heart J; 2005 Aug; 150(2):257-62. PubMed ID: 16086927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension.
    Ferrario CM; Smith RD; Brosnihan B; Chappell MC; Campese VM; Vesterqvist O; Liao WC; Ruddy MC; Grim CE
    Am J Hypertens; 2002 Jun; 15(6):557-64. PubMed ID: 12074359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effects of omapatrilat and lisinopril on circulating neurohormones and cytokines in patients with chronic heart failure.
    Sheth T; Parker T; Block A; Hall C; Adam A; Pfeffer MA; Stewart DJ; Qian C; Rouleau JL;
    Am J Cardiol; 2002 Sep; 90(5):496-500. PubMed ID: 12208409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasopeptidase inhibition: a new concept in blood pressure management.
    Burnett JC
    J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasopeptidase inhibitor reduces inhospital costs for patients with congestive heart failure: results from the IMPRESS trial. Inhibition of Metallo Protease by BMS-186716 in a Randomized Exercise and Symptoms Study in Subjects With Heart Failure.
    Eisenstein EL; Nelson CL; Simon TA; Smitten AL; Lapuerta P; Mark DB
    Am Heart J; 2002 Jun; 143(6):1112-7. PubMed ID: 12075271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The natriuretic peptide neurohormonal system modulation by vasopeptidase inhibitors--the novel therapeutical approach of hypertension treatment.
    Machowska A; Juszczak K; Novak P; Thor P
    Folia Med Cracov; 2009; 50(3-4):35-42. PubMed ID: 21853869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasopeptidase inhibition has beneficial cardiac effects in spontaneously diabetic Goto-Kakizaki rats.
    Grönholm T; Cheng ZJ; Palojoki E; Eriksson A; Bäcklund T; Vuolteenaho O; Finckenberg P; Laine M; Mervaala E; Tikkanen I
    Eur J Pharmacol; 2005 Sep; 519(3):267-76. PubMed ID: 16137672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril.
    Trippodo NC; Fox M; Monticello TM; Panchal BC; Asaad MM
    J Cardiovasc Pharmacol; 1999 Dec; 34(6):782-90. PubMed ID: 10598120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure].
    Latini R
    Ital Heart J Suppl; 2001 Jan; 2(1):83-4. PubMed ID: 11216088
    [No Abstract]   [Full Text] [Related]  

  • 13. Omapatrilat: a unique new agent for the treatment of cardiovascular disease.
    Nawarskas JJ; Anderson JR
    Heart Dis; 2000; 2(3):266-74. PubMed ID: 11728268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasopeptidase inhibitors: potential role in the treatment of heart failure.
    Trindade PT; Rouleau JL
    Heart Fail Monit; 2001; 2(1):2-7. PubMed ID: 12634892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts.
    Blais C; Fortin D; Rouleau JL; Molinaro G; Adam A
    J Pharmacol Exp Ther; 2000 Nov; 295(2):621-6. PubMed ID: 11046097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Omapatrilat for treatment of heart failure].
    Yamazaki T
    Nihon Rinsho; 2007 May; 65 Suppl 5():173-5. PubMed ID: 17571381
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).
    Packer M; Califf RM; Konstam MA; Krum H; McMurray JJ; Rouleau JL; Swedberg K
    Circulation; 2002 Aug; 106(8):920-6. PubMed ID: 12186794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Vasopeptidase inhibitors. Omapatrilat in hypertension and heart failure].
    Heinzl S
    Med Monatsschr Pharm; 2000 Feb; 23(2):38-41. PubMed ID: 10701306
    [No Abstract]   [Full Text] [Related]  

  • 19. Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice.
    Arnal JF; Castano C; Maupas E; Mugniot A; Darblade B; Gourdy P; Michel JB; Bayard F
    Atherosclerosis; 2001 Apr; 155(2):291-5. PubMed ID: 11254898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omapatrilat. Bristol-Myers Squibb.
    Tabrizchi R
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1414-22. PubMed ID: 11890357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.